We recently published an article titled Jim Cramer Discussed 10 Stocks That Can Do Well in December.In this article, we are going to take a look at where McKesson Corporation (NYSE:MCK) stands against the other stocks that can do well in December according to Jim Cramer.
Jim Cramer, the host of Mad Money, recently shared a list of ten stocks he believes will perform well in December. He pointed out that stocks that do well in November tend to continue their strong performance into the final month of the year.
Cramer explained that the beginning of a new month brings attention to the previous month’s performance, and with that, a significant influx of money flows into the market. This money, he said, tends to validate the moves of the largest stocks, creating a cycle where money is immediately put to work, often benefiting the Magnificent Seven.
READ ALSO Jim Cramer’s Lightning Round: 7 Stocks to Watch and Jim Cramer Thinks These 13 Stocks Will Benefit From the New Administration
Cramer also highlighted a common pattern at the end of the year, noting that people tend to make contributions to their retirement accounts when the year is going well. He emphasized that this trend is already visible in the market. When asked why a strong November often translates into a positive December, Cramer pointed to the mechanics of money management. He said that this pattern isn’t new for him, elaborating:
“Before I started my Charitable Trust more than two decades ago, I ran a hedge fund. I was always looking for an edge, and one of the most reliable patterns I found is that, when December rolls around, you mimic the biggest winners of November.”
Cramer recalled how, during his hedge fund days, he would focus on the top-performing stocks of November, buying heavily into those picks and letting them continue to perform through the end of the year. He remarked that this approach has proven to be successful year after year.
In addition to the stocks he recommended, Cramer also noted a category of stocks tied to travel. He mentioned that travel-related industries, including airlines and cruise ships, were particularly strong in November and could continue to show promise in December.
“Now, there are other[s] underneath this list, ones that involve traveling. To me, that means you could buy anything connected to travel, including the airlines… Cruise ships work… But the bottom line: If you want to know what I think could do best in the month of December, or simply what worked best in the month of November, so now you got your marching orders and I say (buy, buy, buy).”
Our Methodology
For this article, we compiled a list of 10 stocks that were discussed by Jim Cramer during a recent episode of Mad Money on December 2. We listed the stocks in ascending order of their hedge fund sentiment as of the third quarter, which was taken from Insider Monkey’s database of 900 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A successful pharmacist in front of shelves of drugs in a community-based oncology pharmacy.
McKesson Corporation (NYSE:MCK)
Number of Hedge Fund Holders: 57
Cramer called McKesson Corporation (NYSE:MCK) a “traditional middleman” and said:
“Ninth is McKesson, a traditional middleman between the drug companies and the drug stores. Now it’s a Trump stock, not because Trump loves the drug distributors, but because I think it was only a matter of time before the Biden-Harris regulars went after these guys. There’s a widespread belief that McKesson… got a big reprieve, rightly or wrongly.”
McKesson (NYSE:MCK) provides healthcare services, including the distribution of pharmaceuticals, medical supplies, and logistics, while offering technology, consulting, and support solutions for healthcare providers, biopharma companies, and patients. As seen in its recently reported second-quarter fiscal 2025 earnings, the company’s largest unit by revenue is the U.S. Pharmaceutical segment.
It specializes in distributing drugs for the treatment of complex conditions, such as cancer. In the second quarter, sales in this segment grew by 23% to reach $85.7 billion, driven by higher prescription volumes, specialty products, and GLP-1 medications. For the second quarter of fiscal 2025, the company reported a total revenue of $93.65 billion, which surpassed analysts’ expectations. This growth was primarily fueled by strong performance in the U.S. Pharmaceutical segment. Looking ahead, McKesson’s (NYSE:MCK) fiscal 2025 guidance anticipates a 16% to 19% increase in revenue from the U.S. Pharmaceutical segment, along with a 9% to 11% rise in operating profit.
Overall MCK ranks 3rd on our list of the stocks that will do well in December according to Jim Cramer. While we acknowledge the potential of MCK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MCK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
